Original Research
Published on 30 Oct 2023
Fanconi anemia pathway regulation by FANCI in prostate cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1260826
- 2,191 views
- 2 citations
Type at least 3 characters
1,771 articles
Articles
Review
Published on 27 Oct 2023
Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1278282
- 2,891 views
Review
Published on 26 Oct 2023
The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1261090
- 2,846 views
- 1 citation
Original Research
Published on 25 Oct 2023
Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1240868
- 1,664 views
- 1 citation
Review
Published on 24 Oct 2023
Lung cancer organoids: models for preclinical research and precision medicine
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1293441
- 7,568 views
- 5 citations
Case Report
Published on 18 Oct 2023
Immunohistochemistry combined with NGS to assist the differential diagnosis of multiple primary lung cancer with lymph node metastasis: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1260759
- 1,292 views
Case Report
Published on 18 Oct 2023
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1241475
- 1,814 views
- 3 citations
Brief Research Report
Published on 18 Oct 2023
Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1181375
- 1,198 views
- 1 citation
Review
Published on 16 Oct 2023
Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1216289
- 3,015 views
- 1 citation
Original Research
Published on 16 Oct 2023
The anti-cancer efficacy of a novel phenothiazine derivative is independent of dopamine and serotonin receptor inhibition
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1295185
- 1,795 views
- 2 citations
Original Research
Published on 10 Oct 2023
Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1156647
- 1,941 views
- 2 citations
Case Report
Published on 05 Oct 2023
Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1252221
- 1,773 views
- 1 citation
Review
Published on 04 Oct 2023
Use and accuracy of decision support systems using artificial intelligence for tumor diseases: a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1224347
- 3,677 views
- 5 citations
Original Research
Published on 29 Sep 2023
Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1230647
- 2,332 views
- 2 citations
Systematic Review
Published on 29 Sep 2023
Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1258287
- 2,088 views
- 1 citation
Retraction
Published on 28 Sep 2023
Retraction: AnnexinA5 might suppress the phenotype of human gastric cancer cells via ERK pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1294881
- 1,130 views